Pharma-Bio Serv Inc (PBSV) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Pharma-Bio Serv Inc $0.15, price $0.44, upside -65.9%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pharma-Bio Serv Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.2373 – $1.26 · fair‑value band $0.1400 – $0.1700 · the $0.4400 price screens above the $0.1500 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Pharma-Bio Serv in your weekly email
Every Wednesday you see whether Pharma-Bio Serv is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.
Show more
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and process support. It serves pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Stock analysis
Pharma-Bio Serv Inc (PBSV) currently trades at $0.4400, while our model-based Fair Value estimate is $0.1500, implying the stock looks roughly 193.3% overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of $0.7200 per share, and 2 of the 4 models we run sit above the $0.4400 price.
Bear case: the DCF Models group reads lowest at $0.1900, and 2 of the 4 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1400 (bear) to $0.1700 (bull), the price of $0.4400 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Pharma-Bio Serv Inc reported revenue of $9.0M in FY2025 versus $20.1M in FY2021, a compound −18.2%/yr. Reported net income was −$100K in FY2025.
Key figures
Market cap $13.1M · P/S ratio 1.43 · Dividend yield 13.2% · Net margin −1.1% · Return on equity 0.6% · Return on assets (EBIT) −3.5% · Operating margin 5.4% · Revenue (TTM) $9.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −66%, PBSV screens richer than that median.
Fair Value models
Bear $0.1400Fair Value $0.1500Bull $0.1700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.0%
Start year 2020 (pandemic). Over 10 years: −9.1% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.3% (2020) → −7.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 134 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−66% · Below median
Profitability
Return on equity (TTM)1% · Below median
Return on assets−2% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)5% · Above median
Growth and dividend
Revenue growth12% · Above median
Dividend yield (TTM)13.2% · Top 25%
Balance sheet
Debt / equity0.05× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B1.10× · Cheaper than median
P/S (TTM)1.43× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 3
FUTURE (revenue growth)59· sector 34
PAST (return on equity)2· sector 5
HEALTH (low debt)97· sector 98
DIVIDEND (yield)100· sector 48
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Pharma-Bio Serv Inc (PBSV) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.1500 versus a price of $0.4400, about −66% upside (overvalued).
What is the fair value of PBSV?
Our model-based fair value for Pharma-Bio Serv Inc is $0.1500 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.4400.
What is the quality score of PBSV?
Pharma-Bio Serv Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharma-Bio Serv Inc (PBSV)?
Our model-based price target is the fair value of $0.1500 (as of Sep 23, 2026) from 4 valuation models. Cautious scenario $0.1400, optimistic scenario $0.1700. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharma-Bio Serv Inc stock forecast for 2026?
Our models put fair value at $0.1500, about −66% upside versus a price of $0.4400 (overvalued). Cautious scenario $0.1400, optimistic scenario $0.1700. The calculation is refreshed regularly with new filings.
What is the revenue of Pharma-Bio Serv Inc (PBSV)?
Pharma-Bio Serv Inc reported trailing-twelve-month revenue of about $9.1M (latest available figure, as of Sep 23, 2026).
Does Pharma-Bio Serv Inc pay a dividend?
Pharma-Bio Serv Inc currently shows a dividend yield of about 13.18% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Pharma-Bio Serv Inc (PBSV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharma-Bio Serv Inc it is $0.1500 per share (as of Sep 23, 2026), against a price of $0.4400. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Pharma-Bio Serv Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PBSV trades above its calculated fair value: price $0.4400, fair value $0.1500, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PBSV?
No. The price is what the market pays today ($0.4400); the fair value is what the company's own numbers justify ($0.1500). For Pharma-Bio Serv Inc the two are $0.2900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharma-Bio Serv Inc worth?
The market values Pharma-Bio Serv Inc at about $13.1M (market capitalisation, as of Sep 23, 2026). Per share that is $0.4400; our models calculate a fair value of $0.1500 per share.
What do the bullish and bearish scenarios say about PBSV?
Our models span a range for Pharma-Bio Serv Inc: cautious scenario $0.1400, base $0.1500, optimistic $0.1700 per share (as of Sep 23, 2026, price $0.4400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharma-Bio Serv Inc (PBSV)?
Balance-sheet figures for Pharma-Bio Serv Inc (as of Sep 23, 2026): return on equity 0.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is PBSV from its 52-week high?
Pharma-Bio Serv Inc trades at $0.4400, about 25% below its 52-week high of $0.5844 and 12% above the low of $0.3918 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1500 is for.
Which stocks are comparable to Pharma-Bio Serv Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharma-Bio Serv Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.4400, calculated fair value $0.1500 (−66%), Quality Score 65/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PBSV calculated?
We run Pharma-Bio Serv Inc through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Pharma-Bio Serv Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharma-Bio Serv Inc (PBSV)?
The closing price on Sep 23, 2026 was $0.4400. Our model-based fair value is $0.1500, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharma-Bio Serv Inc right now?
The price sits above even our optimistic bull case ($0.1700). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Pharma-Bio Serv Inc
How large is the market capitalisation of Pharma-Bio Serv Inc (PBSV)?
The market capitalisation of Pharma-Bio Serv Inc is $13.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharma-Bio Serv Inc (PBSV)?
The price-to-sales ratio of Pharma-Bio Serv Inc is 1.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Pharma-Bio Serv Inc (PBSV)?
The dividend yield of Pharma-Bio Serv Inc is 13.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharma-Bio Serv Inc (PBSV)?
The net margin of Pharma-Bio Serv Inc is −1.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharma-Bio Serv Inc (PBSV)?
The return on equity (ROE) of Pharma-Bio Serv Inc is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharma-Bio Serv Inc (PBSV)?
On an EBIT basis the return on assets of Pharma-Bio Serv Inc is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharma-Bio Serv Inc (PBSV)?
The operating margin of Pharma-Bio Serv Inc is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharma-Bio Serv Inc (PBSV)?
Revenue at Pharma-Bio Serv Inc is growing +11.8% versus a year earlier (3y avg −22.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharma-Bio Serv Inc (PBSV)?
Earnings per share at Pharma-Bio Serv Inc are growing +150% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pharma-Bio Serv Inc (PBSV) generate?
The free cash flow of Pharma-Bio Serv Inc is −$222K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Pharma-Bio Serv Inc in the live analysis
One click puts Pharma-Bio Serv Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026